Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company company information, Employees & Contact Information

Explore related pages

Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company email format Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company management contacts

Related company profiles:

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

Company Details

Employees
75
Founded
-
Address
4850 W 78th St, Indianapolis,indiana 46268,united States
Phone
(317) 543-9957
Industry
Biotechnology
Website
pointbiopharma.com
Keywords
Radioligand, Radiopharmaceutical, Cancer, Oncology.
HQ
Indianapolis, Indiana
Competitors
Clarity Pharmaceuticals, Curium Pharma, Eli Lilly and Company, Telix Pharmaceuticals Limited, Radiopharm Theranostics, Fusion Pharmaceuticals, Lantheus, Pfizer, Novo Nordisk, Novartis.
Looking for a particular Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company employee's phone or email?

Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company Questions

News

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies - PR Newswire

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies PR Newswire

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands - GlobeNewswire

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands GlobeNewswire

POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials - Seeking Alpha

POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials Seeking Alpha

177Lu-PNT2002 shows initial safety and efficacy in mCRPC - Urology Times

177Lu-PNT2002 shows initial safety and efficacy in mCRPC Urology Times

Eli Lilly extends tender offer deadline for Point Biopharma shares on low participation - Reuters

Eli Lilly extends tender offer deadline for Point Biopharma shares on low participation Reuters

Point Biopharma insiders to reap millions from Lilly deal - Inside INdiana Business

Point Biopharma insiders to reap millions from Lilly deal Inside INdiana Business

Lilly to enter radioligand therapy space with POINT Biopharma buy - FirstWord Pharma

Lilly to enter radioligand therapy space with POINT Biopharma buy FirstWord Pharma

Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion - statnews.com

Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion statnews.com

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) - GlobeNewswire

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) GlobeNewswire

Eli Lilly extends tender offer to buy Point Biopharma after low participation - Reuters

Eli Lilly extends tender offer to buy Point Biopharma after low participation Reuters

POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights - GlobeNewswire

POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights GlobeNewswire

Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal - Reuters

Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal Reuters

POINT Biopharma Expands Its Research with Next-Generation - GlobeNewswire

POINT Biopharma Expands Its Research with Next-Generation GlobeNewswire

Lantheus and POINT Biopharma Announce Positive Topline - GlobeNewswire

Lantheus and POINT Biopharma Announce Positive Topline GlobeNewswire

POINT Biopharma Announces Successful USD $20M Series A - GlobeNewswire

POINT Biopharma Announces Successful USD $20M Series A GlobeNewswire

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members - GlobeNewswire

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members GlobeNewswire

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock - GlobeNewswire

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock GlobeNewswire

Lantheus and POINT Biopharma Announce Strategic - GlobeNewswire

Lantheus and POINT Biopharma Announce Strategic GlobeNewswire

Point Biopharma Launches With Radiopharmaceutical Development Focus - GlobeNewswire

Point Biopharma Launches With Radiopharmaceutical Development Focus GlobeNewswire

POINT Biopharma and Bach Biosciences announce licensing and - GlobeNewswire

POINT Biopharma and Bach Biosciences announce licensing and GlobeNewswire

Lilly Completes $1.4 Billion Acquisition of Point Biopharma - CHEManager

Lilly Completes $1.4 Billion Acquisition of Point Biopharma CHEManager

FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC - Targeted Oncology

FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC Targeted Oncology

POINT Biopharma shareholders get long-awaited radioligand therapy data - FirstWord Pharma

POINT Biopharma shareholders get long-awaited radioligand therapy data FirstWord Pharma

Lilly to surf radiopharmaceutical wave with $1.4B acquisition of Point Biopharma - Fierce Biotech

Lilly to surf radiopharmaceutical wave with $1.4B acquisition of Point Biopharma Fierce Biotech

Lilly Deepens Oncology Pipeline with $1.4B Point Biopharma Purchase - BioSpace

Lilly Deepens Oncology Pipeline with $1.4B Point Biopharma Purchase BioSpace

Former POINT Biopharma CEO, Joe McCann, Joins TAG1 Board of Directors to Advance Isotope Access in Radiopharmaceuticals - PR Newswire

Former POINT Biopharma CEO, Joe McCann, Joins TAG1 Board of Directors to Advance Isotope Access in Radiopharmaceuticals PR Newswire

Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition - MedCity News

Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition MedCity News

Lilly buys radiopharmaceutical startup Point Biopharma for $1.4B - Inside INdiana Business

Lilly buys radiopharmaceutical startup Point Biopharma for $1.4B Inside INdiana Business

Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies - Investopedia

Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies Investopedia

POINT Biopharma Global (PNT) Stock Price, News & Analysis - MarketBeat

POINT Biopharma Global (PNT) Stock Price, News & Analysis MarketBeat

Lilly, Point Biopharma accused of patent infringement of cancer drugs - Inside INdiana Business

Lilly, Point Biopharma accused of patent infringement of cancer drugs Inside INdiana Business

Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase - Seeking Alpha

Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase Seeking Alpha

Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover - Seeking Alpha

Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover Seeking Alpha

Point Biopharma: Interesting, Novel Radiotherapy Developer (NASDAQ:PNT) - Seeking Alpha

Point Biopharma: Interesting, Novel Radiotherapy Developer (NASDAQ:PNT) Seeking Alpha

Point Biopharma is heading to $13, says Raymond James - Cantech Letter

Point Biopharma is heading to $13, says Raymond James Cantech Letter

Eli Lilly acquires Point Biopharma for $1.4B: Employee rights - Samfiru Tumarkin LLP

Eli Lilly acquires Point Biopharma for $1.4B: Employee rights Samfiru Tumarkin LLP

Toronto-founded cancer therapy maker Point Biopharma to list on Nasdaq with SPAC merger - The Globe and Mail

Toronto-founded cancer therapy maker Point Biopharma to list on Nasdaq with SPAC merger The Globe and Mail

Companies like Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Novartis logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Novartis

79.78K
Clarity Pharmaceuticals logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Clarity Pharmaceuticals

65
Eli Lilly and Company logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Eli Lilly And Company

51.50K
Telix Pharmaceuticals Limited logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Telix Pharmaceutical...

601
Novo Nordisk logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Novo Nordisk

66.81K
Pfizer logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Pfizer

100.69K
Radiopharm Theranostics logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Radiopharm Theranostics

21
Lantheus logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Lantheus

1.22K
Curium Pharma logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Curium Pharma

1.83K
Fusion Pharmaceuticals logo - Similar company to Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company

Fusion Pharmaceuticals

149

Top Point Biopharma, A Wholly Owned Subsidiary Of Eli Lilly And Company Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant